Department of Health
and Human Services (HHS)
and Human Services (HHS)
June 18, 2021
RFA-HL-21-013 - Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)
National Heart, Lung, and Blood Institute (NHLBI)
The purpose of this Notice is to alert potential applicants to a change in Key Dates and Award Information for RFA-HL-21-013, "Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)".
The following sections of RFA-HL-21-013, "Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)" have been modified:
Part 1. Key Dates
Currently Reads:
|
Open Date (Earliest Submission Date) |
June 24, 2020 |
|
Letter of Intent Due Date(s) |
30 days prior to the application due date |
| Application Due Date(s) |
July 24, 2020, March 19, 2021, June 1, 2022. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
| AIDS Application Due Date(s) | Not Applicable |
| Scientific Merit Review | December 2020, April 2021, January 2023 |
| Advisory Council Review | January 2021, May 2021, January 2023 |
| Earliest Start Date | April 2021, August 2021, April 2023 |
| Expiration Date | June 02, 2022 |
Modified to Read (changes shown in bold italics):
| Open Date (Earliest Submission Date) | June 24, 2020 |
| Letter of Intent Due Date(s) | 30 days prior to the application due date |
| Application Due Date(s) |
July 24, 2020, March 19, 2021, January 10, 2022, June 1, 2022. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
| AIDS Application Due Date(s) | Not Applicable |
| Scientific Merit Review | December 2020, April 2021, April 2022, November 2022 |
| Advisory Council Review | January 2021, May 2021, May 2022, January 2023 |
| Earliest Start Date | April 2021, August 2021, July 2022, April 2023 |
| Expiration Date | June 02, 2022 |
Part 2. Section II. Award Information
Currently Reads:
Funds Available and Anticipated Number of Awards
NHLBI intends to commit total costs up to $630,000 in FY2021, $315,000 in FY2022, and $630,000 in FY2023 to fund up to two new awards in FY2021, one in FY2022, and two in FY2023. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Award Budget
Application budgets may not exceed direct costs of $200,000 per year. Actual budget amounts will depend on annual appropriations.
Investigators are encouraged to request what is well-justified for their research program.
Modified to Read (changes shown in bold italics):
Funds Available and Anticipated Number of Awards
NHLBI intends to commit total costs up to $900,000 in FY2022, and $450,000 in FY2023, to fund up to two new awards in FY2022, one in FY2023. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Award Budget
Application budgets may not exceed direct costs of $270,000 per year. Actual budget amounts will depend on annual appropriations.
Investigators are encouraged to request what is well-justified for their research program.
All other aspects of this FOA remain unchanged.
Antonello Punturieri, MD, PhD
Division of Lung Diseases
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0233
Email: [email protected]